Loading…
Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc (IRWD) is listed on NASDAQ and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Boston, United States and has 100 employees. The company is worth $589.91M and trades at 4.6x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $296.15M in fiscal 2025, down 15.7% from the year before. Net income was $24.02M. The share price is 38.2% below its 52-week high of $5.78. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $33.65M. In that quarter, 1 of them opened or added to the position and 2 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -68.4% over 5Y.
today you would have $274.08▼ -72.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 16 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $3.37 | $4.43 | $11.44 | $12.39 | $11.66 | $11.39 | $13.31 | $8.68 | $12.55 | $12.81 | $9.71 | $12.83 | $9.72 | $9.28 | $10.03 | $8.67 | |
| P/E | 17.3x | 22.5x |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 24.3 among peers in the sector.
Median P/E of 17.3 across this company’s own years on record.
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AVRAnteris Technologies Global Corp. | $6.05 | — | 2.3x | 0.00% | -74.65% | $589.62M |
| ZVRAZevra Therapeutics Inc | $9.94 | 10.8x | 2.7x | 0.00% | 34.80% | $590.27M |
| WEAVWeave Communications, Inc. | $7.39 | — | 7.0x | 0.00% | -25.08% | $594.53M |
| PBYIPuma Biotechnology Inc |
| 443.0x |
| — |
| 12.9x |
| 3.6x |
| 17.3x |
| 95.1x |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| P/S | 4.6x | 1.9x | 2.0x | 4.0x | 4.7x | 4.5x | 4.7x | 4.9x | 4.6x | — | — | — | — | — | — | 18.1x | 21.2x |
| P/B | 5.8x | — | — | — | 2.9x | 3.1x | 29.3x | — | — | — | — | — | — | — | — | 10.9x | 5.8x |
| EPS | $0.15 | $0.01 | -$6.45 | $0.96 | $3.21 | $0.66 | $0.14 | -$1.85 | -$0.78 | -$0.47 | -$0.84 | -$1.16 | -$1.97 | -$0.57 | -$0.54 | -$0.49 |
| Profit margin | -43.77% | 8.11% | 0.25% | -226.37% | 42.64% | 127.72% | 27.26% | 5.02% | -81.46% | -39.20% | -29.83% | -95.40% | -248.07% | -1192.31% | -48.34% | -98.45% | -118.25% |
| ROE | -59.03% | — | — | — | 26.83% | 87.22% | 169.50% | — | — | -1187.42% | -122.47% | -149.98% | -214.13% | -713.70% | -50.42% | -59.03% | -32.50% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
4 methods answered, across 3 families.
Room for errors in the reported numbers.
+206.5% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| $11.26 |
| 21.2x |
| 4.2x |
| 0.00% |
| 21.97% |
| $581.24M |
| AVTXAvalo Therapeutics, Inc. | $11.27 | — | 1.3x | 0.00% | -36.27% | $604.41M |
| MDXGMimedx Group Inc | $3.93 | 98.3x | 2.7x | 0.00% | 2.88% | $573.52M |